Identification of AL proteins from 10 λ-AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue

References

• Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol. 2016;91(9):947–956.
   PubMed Web of Science ®Google Scholar
• Blancas-Mejía LM, Ramirez-Alvarado M. Systemic amyloidoses. Annu Rev Biochem. 2013;82:745–774.
   PubMed Web of Science ®Google Scholar
• Wechalekar A, Schönland S, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–3427.
   PubMed Web of Science ®Google Scholar
• Bellotti V, Mangione P, Merlini G. Review: immunoglobulin light chain amyloidosis – the archetype of structural and pathogenic variability. J Struct Biol. 2000;130(2–3):280–289.
   PubMed Web of Science ®Google Scholar
• Murphy K, Travers P, Walport M. Janeway immunologie, 7th ed. Heidelberg: Spektrum Akademischer Verlag; 2009.
   Google Scholar
• Gertz RA, Kyle MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45–59.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Zhang Y, Martinez C, et al. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V L germ line gene use and clonal plasma cell burden. Blood. 2001;98(3):714–720.
   PubMed Web of Science ®Google Scholar
• Abraham RS, Geyer SM, Price-Troska TL, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101(10):3801–3808.
   PubMed Web of Science ®Google Scholar
• Berghaus N, Schreiner S, Granzow M, et al. Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement. PLoS One. 2022;17(2):e0264407.
   PubMed Web of Science ®Google Scholar
• Baden EM, Randles EG, Aboagye AK, et al. Structural insights into the role of mutations in amyloidogenesis. J Biol Chem. 2008;283(45):30950–30956.
   PubMed Web of Science ®Google Scholar
• Hurle MR, Helms LR, Li L, et al. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci USA. 1994;91(12):5446–5450.
   PubMed Web of Science ®Google Scholar
• Kazman P, Vielberg MT, Pulido Cendales MD, et al. Fatal amyloid formation in a patient’s antibody light chain is caused by a single point mutation. Elife. 2020;9:e52300.
   PubMed Web of Science ®Google Scholar
• Del Pozo-Yauner L, Wall JS, González Andrade M, et al. The N-terminal strand modulates immunoglobulin light chain fibrillogenesis. Biochem Biophys Res Commun. 2014;443(2):495–499.
   PubMed Web of Science ®Google Scholar
• Rennella E, Morgan GJ, Yan N, et al. The role of protein thermodynamics and primary structure in fibrillogenesis of variable domains from immunoglobulin light chains. J Am Chem Soc. 2019;141(34):13562–13571.
   PubMed Web of Science ®Google Scholar
• Weber B, Hora M, Kazman P, et al. The antibody light-chain linker regulates domain orientation and amyloidogenicity. J Mol Biol. 2018;430(24):4925–4940.
   PubMed Web of Science ®Google Scholar
• Rottenaicher GJ, Weber B, Rührnößl F, et al. Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains. J Biol Chem. 2021;296:100334.
   PubMed Web of Science ®Google Scholar
• Poshusta TL, Sikkink LA, Leung N, et al. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS One. 2009;4(4):e5169.
   PubMed Web of Science ®Google Scholar
• van der Kant R, Karow-Zwick AR, Van Durme J, et al. Prediction and reduction of the aggregation of monoclonal antibodies. J Mol Biol. 2017;429(8):1244–1261.
   PubMed Web of Science ®Google Scholar
• Garofalo M, Piccoli L, Romeo M, et al. Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity. Nat Commun. 2021;12(1):10.
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Chuba JV, Hellman GC, et al. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med. 1990;112(6):455–464.
   PubMed Web of Science ®Google Scholar
• Weber B, Hora M, Kazman P, et al. Domain interactions determine the amyloidogenicity of antibody light chain mutants. J Mol Biol. 2020;432(23):6187–6199.
   PubMed Web of Science ®Google Scholar
• Wall JS, Gupta V, Wilkerson M, et al. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vλ6 proteins. J Mol Recognit. 2004;17(4):323–331.
   PubMed Web of Science ®Google Scholar
• Stevens FJ. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid. 2000;7(3):200–211.
   PubMed Web of Science ®Google Scholar
• Mazzini G, Ricagno S, Caminito S, et al. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation. Febs J. 2022;289(2):494–506.
   PubMed Web of Science ®Google Scholar
• Radamaker L, Karimi-Farsijani S, Andreotti G, et al. Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM. Nat Commun. 2021;12(1):6434.
   PubMed Web of Science ®Google Scholar
• Retter I, Althaus HH, Münch R, et al. VBASE2, an integrative V gene database. Nucleic Acids Res. 2005;33(Database issue):D671–D674.
   PubMedGoogle Scholar
• Howe KL, Achuthan P, Allen J, et al. Ensembl 2021. Nucleic Acids Res. 2021;49(D1):D884–D891.
   PubMed Web of Science ®Google Scholar
• Annamalai K, Liberta F, Vielberg MT, et al. Common fibril structures imply systemically conserved protein misfolding pathways in vivo. Angew Chem Int Ed Engl. 2017;56(26):7510–7514.
   PubMed Web of Science ®Google Scholar
• Wu Z, Roberts DS, Melby JA, et al. MASH explorer: a universal software environment for top-down proteomics. J Proteome Res. 2020;19(9):3867–3876.
   PubMed Web of Science ®Google Scholar
• Niedermeyer THJ, Strohalm M. mMass as a software tool for the annotation of cyclic peptide tandem mass spectra. PLoS One. 2012;7(9):e44913.
   PubMed Web of Science ®Google Scholar
• Gasteiger E, Gattiker A, Hoogland C, et al. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003;31(13):3784–3788.
   PubMed Web of Science ®Google Scholar
• Giudicelli V, Chaume D, Lefranc MP. IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res. 2005;33(Database issue):D256–D261.
   PubMed Web of Science ®Google Scholar
• Kawasaki K, Minoshima S, Nakato E, et al. One-megabase sequence analysis of the human immunoglobulin lambda gene locus. Genome Res. 1997;7(3):250–261.
   PubMed Web of Science ®Google Scholar
• Swindells MB, Porter CT, Couch M, et al. abYsis: integrated antibody sequence and structure-management, analysis, and prediction. J Mol Biol. 2017;429(3):356–364.
   PubMed Web of Science ®Google Scholar
• Gasteiger E, Hoogland C, Gattiker A, et al. Protein identification and Analysis Tools on the ExPASy Server. Proteomics Protoc Handb. 2005;2005:571–607.
   Google Scholar
• Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, et al. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol. 2004;22(10):1302–1306.
   PubMed Web of Science ®Google Scholar
• Gupta R, Brunak S. Prediction of glycosylation across the human proteome and the correlation to protein function. Authors to correct!. 2002;2002:310–322.
   Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera – a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–1612.
   PubMed Web of Science ®Google Scholar
• Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325–2332.
   PubMed Web of Science ®Google Scholar
• Van Gameren II, Hazenberg BPC, Bijzet J, et al. Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. Arthritis Care Res. 2010;62(3):296–301.
   Web of Science ®Google Scholar
• Dispenzieri A, Larson DR, Rajkumar SV, et al. N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. Leukemia. 2020;34(10):2749–2753.
   PubMed Web of Science ®Google Scholar
• Glenner GG. Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts). N Engl J Med. 1980;302(24):1333–1343.
   PubMed Web of Science ®Google Scholar
• Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V(λVI) subgroup of human light chains with amyloidosis AL(λ). J Clin Invest. 1982;70(2):453–460.
   PubMed Web of Science ®Google Scholar
• Lavatelli F, Perlman DH, Spencer B, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics. 2008;7(8):1570–1583.
   PubMed Web of Science ®Google Scholar
• Chelius D, Jing K, Lueras A, et al. Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Anal Chem. 2006;78(7):2370–2376.
   PubMed Web of Science ®Google Scholar
• Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333–366.
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28(2):384–390.
   PubMed Web of Science ®Google Scholar
• Rasche L, Chavan SS, Stephens OW, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8(1):268.
   PubMedGoogle Scholar
• Bellotti V, Merlini G, Bucciarelli E, et al. Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Br J Haematol. 1990;74(1):65–69.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Ramirez-Alvarado M, Dispenzieri A, et al. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. Clin Chem Lab Med. 2008;46(3):335–341.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Livneh A, Gallo G. Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease. Br J Haematol. 2007;136(5):723–728.
   PubMed Web of Science ®Google Scholar
• Swuec P, Lavatelli F, Tasaki M, et al. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. Nat Commun. 2019;10(1):1269.
   PubMedGoogle Scholar
• Schmittschmitt JP, Scholtz JM. The role of protein stability, solubility, and net charge in amyloid fibril formation. Protein Sci. 2003;12(10):2374–2378.
   PubMed Web of Science ®Google Scholar
• Schein CH. Solubility as a function of protein structure and solvent components. Biotechnology. 1990;8(4):308–317.
   PubMed Web of Science ®Google Scholar
• Rennella E, Morgan GJ, Kelly JW, et al. Role of domain interactions in the aggregation of full-length immunoglobulin light chains. Proc Natl Acad Sci USA. 2019;116(3):854–863.
   PubMed Web of Science ®Google Scholar
• Klimtchuk ES, Gursky O, Patel RS, et al. The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain. Biochemistry. 2010;49(45):9848–9857.
   PubMed Web of Science ®Google Scholar
• Lavatelli F, Mazzini G, Ricagno S, et al. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis. J Biol Chem. 2020;295(49):16572–16584.
   PubMed Web of Science ®Google Scholar
• Radamaker L, Lin YH, Annamalai K, et al. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. Nat Commun. 2019;10(1):1103.
   PubMedGoogle Scholar
• Radamaker L, Baur J, Huhn S, et al. Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis. Nat Commun. 2021;12(1):875.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Kelly JW. The kinetic stability of a full-length antibody light chain dimer determines whether endoproteolysis can release amyloidogenic variable domains. J Mol Biol. 2016;428(21):4280–4297.
   PubMed Web of Science ®Google Scholar
• Buxbaum J. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am. 1992;6(2):323–346.
   PubMed Web of Science ®Google Scholar